Epitome Pharmaceuticals identifies, develops and licenses promising medications, concentrating on high-value unmet needs.
Once a remedy has been identified and intellectual property rights secured, we advance the development of the medication. For medications, we clarify regulatory issues through close cooperation with regulatory agencies. Based on our research and the prospects for a specific medication, we may file an IND and initiate Phase I or Phase II trials.
Then Epitome Pharmaceuticals will license its intellectual property to a partner (or partners) with the resources and capabilities to complete clinical trials, secure regulatory approval and bring a product to market most effectively.
Stabilizing Dose-Response of Anticoagulants
Epitome has unraveled the dose-response algorithm for warfarin and other coumarins. Patients’ dose-response curves are stable as long as their medical condition is the same; we can detect shifts of as little as 10% of dose when they receive an interfering drug, and therefore provide guidance for a new optimum dose.COVID-Tea treatment
Our colleague Professor Saverio Bettuzzi tested green tea pills and inhalation in 10 patients in Italy during the COVID surge last fall. The work is now published at COVID | Free Full-Text | Efficacy of a Polyphenolic, Standardized Green Tea Extract for the Treatment of COVID-19 Syndrome: A Proof-of-Principle Study | HTMLNine patients were treated at home with daily visits by a doctor. All recovered at an average of 9 days, max 15 days. Several had signs of progressive disease, especially the older patients. One patient was treated in the hospital. They had with 40% lung consolidation and were on high-flow oxygen. They recovered in 10 days and were negative for virus.
Early Drug Development in Cooperation with the Pharmaceutical Industry
Epitome Pharmaceuticals identifies, develops and licenses promising medications and technologies. Investigation is conducted by reading the scientific literature, discussing anomalies and questions with leaders in their fields, and by statistical reanalysis of published data. Once a remedy has been identified and intellectual property rights secured, we proceed to advance the development of the medication. We clarify regulatory issues through close cooperation with regulatory agencies. Based on our research and the prospects for a specific medication, we may file an IND and initiate Phase I or Phase II trials.
Ultimately, Epitome Pharmaceuticals seeks to license its intellectual property to a partner (or partners) with the resources and capabilities to complete clinical trials, secure regulatory approval and bring a product to market most effectively.